Last reviewed · How we verify
NCT03367013
Lactoferrin Infant Feeding Trial - LIFT_Canada
Phase 3 trial testing Bovine Lactoferrin in Preterm Infant in 453 participants. Completed in 25 November 2024.
27 July 2022
Quick facts
| Lead sponsor | Dr. Elizabeth Asztalos |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 453 |
| Start date | 22 February 2018 |
| Primary completion | 27 July 2022 |
| Estimated completion | 25 November 2024 |
| Sites | 9 locations across Canada |
Drugs / interventions tested
- Bovine Lactoferrin — full drug profile →
- No Bovine Lactoferrin added
Conditions studied
- Preterm Infant — all drugs for Preterm Infant →
- Very Low Birth Weight Infant — all drugs for Very Low Birth Weight Infant →
- Morbidity;Newborn — all drugs for Morbidity;Newborn →
Sponsor
Dr. Elizabeth Asztalos
Who can join
Adults 2 Days to 7 Days, any sex, with Preterm Infant or Very Low Birth Weight Infant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicentre, phase III, 2-arm, masked randomized controlled trial. The primary hypothesis is that oral bovine lactoferrin (bLF), through its antimicrobial, antioxidant and anti-inflammatory properties, will reduce the rate of mortality or major morbidity in very low birth weight (VLBW) preterm infants.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lactoferrin infant feeding trial_Canada (LIFT_Canada): protocol for a randomized trial of adding lactoferrin to feeds of very-low-birth-weight preterm infants.
Asztalos EV, Barrington K, Lodha A, Tarnow-Mordi W, et al · · 2020 · cited 14× · PMID 31996186 · DOI 10.1186/s12887-020-1938-0
Verify or expand the search:
- PubMed search for NCT03367013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bovine Lactoferrin
Trials testing the same drug.
- NCT04526821 — Lactoferrin for Prevention of COVID-19 in Health Care Workers · Phase 2 · terminated
- NCT04432935 — Effect of Lactoferrin on Polio Seroconversion · NA · completed
- NCT06109688 — Effect of Lactoferrin Supplementation on Urinary Tract Infections in Infants. · Phase 3 · completed
Other recruiting trials for Preterm Infant
Currently open trials in the same condition.
- NCT06786039 — Clinical Impact of Non-invasive Neurally Adjusted Ventilatory Assist in Very Preterm Infants · recruiting
- NCT06532695 — Development, ADL, Participation, and Quality of Life in Preterm Infants: Longitudinal Research · recruiting
- NCT07238231 — Taiwan Preterm Infant Database: Analysis and Comparison of Birth Conditions and Exploration of Prognostic Factors · active not recruiting
- NCT03518736 — Does Timing Matter? Supporting Play, Exploration, and Early Developmental Intervention · NA · active not recruiting
- NCT03373721 — Gut Microbiota of Preterm Infants and Full-term Infants at Early Life · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03367013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Elizabeth Asztalos
- Last refreshed: 29 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03367013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing